Abiopharma

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçets Disease

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

FORM 6-KBrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Bridger Aerospace Names Justin Mogford as General Counsel, Further Strengthening Management Team

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

NMG and Government of Canada Execute Updated Binding Offtake and Marketing Framework for Matawinie Graphite

Hillman Recognized by REDI Cincinnati with James A. Wuenker Growth Award for Forest Fair Mall Redevelopment Project

Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

NMG et le gouvernement du Canada signent une entente contraignante d’achat « offtake » et de mise en marché pour le graphite de la mine Matawinie